HK1214841A1 - 分泌异源多肽的方法和组合物 - Google Patents

分泌异源多肽的方法和组合物 Download PDF

Info

Publication number
HK1214841A1
HK1214841A1 HK16102612.6A HK16102612A HK1214841A1 HK 1214841 A1 HK1214841 A1 HK 1214841A1 HK 16102612 A HK16102612 A HK 16102612A HK 1214841 A1 HK1214841 A1 HK 1214841A1
Authority
HK
Hong Kong
Prior art keywords
antibody
polypeptide
antibodies
sequence
antigen
Prior art date
Application number
HK16102612.6A
Other languages
English (en)
Chinese (zh)
Inventor
．馬里基
M．马里基
．萊利
D．E．莱利
Original Assignee
弗.哈夫曼-拉罗切有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 弗.哈夫曼-拉罗切有限公司 filed Critical 弗.哈夫曼-拉罗切有限公司
Publication of HK1214841A1 publication Critical patent/HK1214841A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16102612.6A 2009-11-05 2013-07-23 分泌异源多肽的方法和组合物 HK1214841A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25856509P 2009-11-05 2009-11-05
US61/258,565 2009-11-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK13108610.8A Addition HK1181400B (en) 2009-11-05 2010-11-05 Methods and composition for secretion of heterologous polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK13108610.8A Division HK1181400B (en) 2009-11-05 2010-11-05 Methods and composition for secretion of heterologous polypeptides

Publications (1)

Publication Number Publication Date
HK1214841A1 true HK1214841A1 (zh) 2016-08-05

Family

ID=43446780

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102612.6A HK1214841A1 (zh) 2009-11-05 2013-07-23 分泌异源多肽的方法和组合物

Country Status (20)

Country Link
US (4) US8361744B2 (enExample)
EP (1) EP2496601B1 (enExample)
JP (2) JP6173690B2 (enExample)
KR (1) KR101968766B1 (enExample)
CN (2) CN105274170A (enExample)
AU (1) AU2010314981B2 (enExample)
BR (1) BR112012010153B1 (enExample)
CA (1) CA2780143A1 (enExample)
ES (1) ES2636971T3 (enExample)
HK (1) HK1214841A1 (enExample)
HR (1) HRP20171136T1 (enExample)
IL (1) IL219269A (enExample)
MX (1) MX2012005168A (enExample)
NZ (1) NZ598901A (enExample)
PL (1) PL2496601T3 (enExample)
RU (1) RU2585488C2 (enExample)
SI (1) SI2496601T1 (enExample)
TW (1) TWI600760B (enExample)
WO (1) WO2011057120A1 (enExample)
ZA (1) ZA201202107B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513427A (ja) * 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
EP2480661A1 (en) 2009-09-24 2012-08-01 UCB Pharma, S.A. Bacterial host strain
TWI600760B (zh) 2009-11-05 2017-10-01 建南德克公司 分泌異源多肽之方法及組合物
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
MX348738B (es) 2011-07-13 2017-06-27 Ucb Pharma Sa Cepa huesped bacteriana que expresa dsbc recombinante.
AU2012340826A1 (en) * 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US9828415B2 (en) 2013-01-30 2017-11-28 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
WO2015139046A1 (en) * 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
ES2799503T3 (es) 2014-10-31 2020-12-18 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
EP3215525B1 (en) * 2014-11-05 2020-07-29 Genentech, Inc. Methods of producing two chain proteins in bacteria
JP6739428B2 (ja) 2014-11-05 2020-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エフェクター機能抑制型ヒトまたはヒト化薬物抗体に対する抗薬物抗体の決定方法
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
ES2761726T3 (es) * 2015-03-06 2020-05-20 Hoffmann La Roche DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
KR20180108567A (ko) 2015-10-22 2018-10-04 주노 테라퓨틱스 게엠베하 형질도입을 위한 방법, 키트, 제제 및 장치
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
JP7021099B2 (ja) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
GB2594002B (en) * 2016-06-24 2022-04-13 Univ South Carolina Inhibin as targetable regulators of angiogenesis
IL270142B2 (en) 2017-04-27 2025-05-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
KR102078292B1 (ko) * 2017-05-30 2020-02-19 주식회사 종근당 신규한 항 c-Met 항체 및 이의 용도
JP7658905B2 (ja) * 2019-01-23 2025-04-08 ジェネンテック， インコーポレイテッド 真核宿主細胞において多量体タンパク質を産生する方法
EP4100534A4 (en) * 2020-02-07 2024-06-05 Xbrane Biopharma AB Synthetically evolved dna constructs for regulating signal peptide performance as well as vectors, host cells and recombinant proteins thereof
SE544059C2 (en) * 2020-02-07 2021-11-30 Cloneopt Ab Synthetically evolved dna constructs for regulating signal peptide performance as well as vectors and host cells thereof
SE543946C2 (en) * 2020-02-07 2021-10-05 Cloneopt Ab Synthetically evolved dna constructs for regulating signal peptide performance as well as vectors and host cells thereof
SE543945C2 (en) * 2020-02-07 2021-10-05 Cloneopt Ab Synthetically evolved DNA constructs for regulating signal peptide performance as well as vectors and host cells thereof
AU2022349814A1 (en) * 2021-09-24 2024-05-02 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
CN115873790A (zh) * 2021-09-27 2023-03-31 金涌长生医学生物科技股份有限公司 一种蜕膜胎盘间充质干细胞及其在制备促进血管新生药物组合物中的用途

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
DE3219645A1 (de) 1982-05-25 1983-12-01 Beiersdorf Ag, 2000 Hamburg Steinschlagfeste selbstklebe-dekorfolie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
DE4417598A1 (de) * 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5840523A (en) * 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5747662A (en) 1995-03-01 1998-05-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6242177B1 (en) 1995-03-01 2001-06-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
MXPA02007190A (es) 2000-01-25 2003-02-12 Genentech Inc Proteina relacionada a liv-1, polinucleotidos que codifican para la misma y uso de la misma para el tratamiento de cancer.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
RU2287574C2 (ru) 2000-12-14 2006-11-20 Дженентек, Инк. БАКТЕРИЯ Е.coli, ПРОДУЦИРУЮЩАЯ ГЕТЕРОЛОГИЧНЫЙ ПОЛИПЕПТИД, И СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
DE60135498D1 (de) 2000-12-14 2008-10-02 Genentech Inc Produktion von ganzen Antikörpern in prokaryontischen Zellen
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1908769A1 (en) 2001-08-27 2008-04-09 Genentech, Inc. A system for antibody expression and assembly
JP4461210B2 (ja) 2001-08-27 2010-05-12 ジェネンテック， インコーポレイテッド 抗体発現系とその構築法
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
NZ538996A (en) * 2002-10-31 2008-04-30 Genentech Inc Methods and compositions for increasing antibody production
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
US20050032173A1 (en) 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2006042158A2 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
EP1868648B1 (en) 2005-03-25 2015-04-15 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
AU2006268780B2 (en) 2005-07-08 2011-03-24 University Of Zurich Phage display using cotranslational translocation of fusion polypeptides
WO2008089132A2 (en) * 2007-01-12 2008-07-24 Cornell Research Foundation, Inc. Genetic selection for protein folding and solubility in the bacterial periplasm
EP2176291A1 (en) * 2007-08-10 2010-04-21 Wacker Chemie AG Expression of full length igg and secretion into the culture medium of prokaryotic cells
JP2011513427A (ja) 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
TWI600760B (zh) 2009-11-05 2017-10-01 建南德克公司 分泌異源多肽之方法及組合物
EP3264089A1 (en) 2010-08-31 2018-01-03 Genentech, Inc. Biomarkers and methods of treatment
AU2012275233A1 (en) 2011-06-30 2013-11-28 Genentech, Inc. Anti-c-met antibody formulations
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
AU2012340826A1 (en) 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies

Also Published As

Publication number Publication date
JP2016152802A (ja) 2016-08-25
US20110111408A1 (en) 2011-05-12
BR112012010153A2 (pt) 2020-08-18
WO2011057120A1 (en) 2011-05-12
EP2496601B1 (en) 2017-06-07
NZ598901A (en) 2014-08-29
TWI600760B (zh) 2017-10-01
RU2012123010A (ru) 2013-12-10
TW201122102A (en) 2011-07-01
ZA201202107B (en) 2013-05-29
BR112012010153B1 (pt) 2022-05-03
CN102933600B (zh) 2015-11-25
US10227416B2 (en) 2019-03-12
CN102933600A (zh) 2013-02-13
CA2780143A1 (en) 2011-05-12
HRP20171136T1 (hr) 2017-10-06
US20200148783A1 (en) 2020-05-14
AU2010314981B2 (en) 2015-07-02
ES2636971T3 (es) 2017-10-10
JP6173690B2 (ja) 2017-08-02
EP2496601A1 (en) 2012-09-12
IL219269A (en) 2017-03-30
US8735098B2 (en) 2014-05-27
HK1181400A1 (en) 2013-11-08
RU2585488C2 (ru) 2016-05-27
KR101968766B1 (ko) 2019-04-12
CN105274170A (zh) 2016-01-27
PL2496601T3 (pl) 2017-10-31
IL219269A0 (en) 2012-06-28
JP2013509867A (ja) 2013-03-21
AU2010314981A1 (en) 2012-04-12
US20140371429A1 (en) 2014-12-18
KR20120113705A (ko) 2012-10-15
MX2012005168A (es) 2012-06-08
SI2496601T1 (sl) 2017-09-29
US20130096280A1 (en) 2013-04-18
US8361744B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
CN102933600B (zh) 分泌异源多肽的方法和组合物
KR100956913B1 (ko) 치료제로서 유용한 일가 항체 단편
CN106103730B (zh) 用于分泌异源多肽的方法和组合物
CA3093034A1 (en) Single-domain antibodies against lag-3 and uses thereof
CN102648211B (zh) 抗hepsin抗体及其使用方法
HK1181400B (en) Methods and composition for secretion of heterologous polypeptides
AU2013203389A1 (en) Methods and composition for secretion of heterologous polypeptides
JP2025527465A (ja) 細胞内在標的に対する抗体を産生する無細胞方法
HK1190727B (en) Anti-ephb4 antibodies and methods using same
HK1190727A1 (zh) 抗ephb4抗體及其使用方法
HK1187352A1 (en) Anti-ephrinb2 antibodies and methods using same
HK1171032B (en) Anti-hepsin antibodies and methods using same
HK1230663A1 (en) Methods and compositions for secretion of heterologous polypeptides
HK1187352B (en) Anti-ephrinb2 antibodies and methods using same